EMG laboratory considerations – Demyelinating neuropathies. Weakness. Shawn Jorgensen Albany Medical Center AAPM&R Annual Assembly 2014. Financial disclosures. None. Possible neuropathy.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Dyck PJ, Thomas PK. Peripheral Neuropathy. Philadelphia, PA:Elsevier Saunders, 2005.
Jacobs BC, Rothbarth PH, Van derMeche, et al. The spectrum of antecedent infections in Guillain-Barre syndrome. A case-control study. Neurology 1998;51:1110-1115.
Vucic S, Kiernan MC, Cornblath DR. Guillain-Barre syndrome: an update. J ClinNeurosci 2009;16(6):733-741.
Gordon PH, Wilbourne AJ. Early electrodiagnostic findings in Guillain-Barre syndrome. Arch Neurol 2001;58:913-917.
Albers JW, Donofrio PD, McGonagle TK. Sequential electrodiganostic abnormalities in acute inflammatory demyelinatingpolyradiculoneuropathy. Muscle Nerve 1985;8:528-539.
Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, Swan AV. Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange/SandoglobulinGuillain-Barre Syndrome Trial Group. Ann Neurol 1998;44:780-788.
Cornblath DR, Asbury AK, Albers JW, et al. Research criteria for diagnosis of chronic inflammatory demyelinatingpolyneuropathy (CIDP). Neurology 1991;41:617-618.
Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinatingpolyneuropathies. Muscle Nerve 2001:24:311-324.
Berger AR, Bradley WG, Brannagan TH, Busis NA, Cros DP, Dalakas MC, Danon MJ, Donofrio P, Engel WK, England JD, Feldman EL, Freeman RL, Kinsella LJ, Lacomis D, Latov N, Menkes DL, Sander HW, Thomas FP, Triggs WJ, Windebank AJ. Wolfe GI; Neuropathy Association, Medical Advisory Committee. Guidelines for the diagnosis and treatment of chronic inflammatory demyelinatingpolyneuropathy. J Peripher Nerve Syst 2003;8:282-284.
Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldetein J, Graves M, Gorson K, Hahn AF, Hughes RA, Katz J, Lewis RA, Parry GJ, van Doorn P, Cornblat DR. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinatingpolyneuropathy. J NeurolSci 2009;277:1-8.
Van den bergh PY, Pieret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinatingpolyradiculoneuropathy.. Muscle Nerve 2004;29:565-574.
Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinatingpolyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – First Revision. J PeripherNervSyst 2010;15:1-9.
Kornberg AJ, Pestronk A. The clinical and diagnostic role of anti-GM1 antibody testing. Muscle Nerve 1994;17:100-104.
Olney RK, Lewis RA, Putnam TD, Campelione JV Jr, American Association of Electrodiagnostic Medicine. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 2003:27:117-121.
Van asseldonk JTH, Van den Berg LH, Van den Berg-Vos RM, Wieneke GH, Wokke JHJ, Franssen H. Demyelination and axon loss in multifocal motor neuropathy: distribution and relation to weakness. Brain 2003;126:186-198.